TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00601692

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Given 5 days a week for 3 weeks

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Given 5 days a week for 3 weeks
Study: NCT00565149

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PROOF
Description: dietary overfeeding with high, low or normal protein content

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PROOF
Description: dietary overfeeding with high, low or normal protein content
Study: NCT03288701

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Seca medical Body Composition Analyser 515
Description: Comparison of reduction of whole body water and body weight in patients with decompensated heart failure under forced diuretic treatment
Study: NCT00834496

Intervention type: PROCEDURE
Intervention: Liver biopsy
Description: percutaneous liver biopsy
Study: NCT03640286

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: VeSTAL
Description: The aim of this study is to evaluate the efficacy of non-invasive electrical vestibular nerve stimulation in combination with a lifestyle modification program, as a method of reducing excess body weight and body fat, as compared to a sham device in combination with the same lifestyle modification program.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: VeSTAL
Description: The aim of this study is to evaluate the efficacy of non-invasive electrical vestibular nerve stimulation in combination with a lifestyle modification program, as a method of reducing excess body weight and body fat, as compared to a sham device in combination with the same lifestyle modification program.
Study: NCT01562834

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: somatropin
Description: Initial dosage 0.5 IU/day, injected subcutaneously (s.c., under the skin) once daily. Dosage will be adjusted monthly depending on clinical safety up to a maximum dose of 3 IU/day. Subjects are treated for six months (randomised trial period) followed by an 12-month open-label trial period with somatropin.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Initial dosage 0.5 IU/day, injected subcutaneously (s.c., under the skin) once daily. Dosage will be adjusted monthly depending on clinical safety up to a maximum dose of 3 IU/day. Subjects are treated for six months. After treatment in the randomised trial period, placebo will be discontinued.
Study: NCT00229658

Intervention type: DRUG
Intervention: pramlintide acetate
Description: Subcutaneous injection prior to each major meal

Intervention type: DRUG
Intervention: pramlintide acetate
Description: Subcutaneous injection prior to each major meal
Study: NCT03562338

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual Therapy and Exercise (Physiotherapy Intervention)
Description: Participants in this group will receive a 6-weeks program of mobilization and progressive exercise for the neck flexors, 2 times a week.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care (Physiotherapy Intervention)
Description: Participants in this group will receive usual care in physiotherapy during the 6-weeks period.
Study: NCT01768689

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adherence-encouraging interventions - Group meeting
Description: One Group meeting (at the beginning of the intervention period) for all participants, focusing on issues relevant to adherence improvement

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adherence-encouraging interventions - Individual meetings
Description: Individual meetings focusing on adherence issues with a multidiscilinary team

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adherence-encouraging interventions - Monthly phone calls
Description: Monthly phone calls to detect urgent adherence-related issues
Study: NCT02796729

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging
Description: MRI offers excellent images of the brain and is an important tool for diagnosing metastatic brain tumors. MRI scans are often used to plan treatments such as surgery and radiotherapy. When imaging participants with metastatic brain tumors, a contrast agent is often injected intravenously to highlight the relatively small tumours in the MRI. The standard metal-based MRI contrast agent is Health Canada approved and contains a material called gadolinium. MRI studies that use gadolinium-based contrast agents are called gadolinium enhanced MRI.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadovist (Gadobutrol)
Description: Gadobutrol (INN) (Gd-DO3A-butrol) is a gadolinium-based MRI contrast agent (GBCA).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 50% dextrose solution
Description: 50% Dextrose Injection, USP is a sterile, nonpyrogenic, hypertonic solution of dextrose in water for intravenous injection.
Study: NCT05342246

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endodontic retreatment
Description: retreatment of the patent root canal only without attempt to retrieve the separated instrument

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endodontic retreatment
Description: retreatment of the patent root canal only without attempt to retrieve the separated instrument
Study: NCT03551379

Intervention type: DEVICE
Intervention: Double Balloon Endoluminal Platform
Description: A DBA platform will be use din this registry study to facilitate ESD
Study: NCT04174339

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: Subjects receive SHR-1210 intravenously, Dosage form: lyophilised powder, Strength: 200 mg /vial，d1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib Mesylate
Description: Subjects receive Apatinib orally, Dosage form: tablet, Strength: 250 mg/tablet，TID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: POF
Description: The POF regimen consisted of a 3-hour infusion of paclitaxel (135 mg/m2) followed by oxaliplatin (85 mg/m2) and Calcium Levofolinate (200 mg/m2).Subsequently, a 46-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating the cycle every 14 days.
Study: NCT00370383

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: erlotinib 150 mg/day once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: erlotinib 150 mg/day once daily
Study: NCT00565149

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PROOF
Description: dietary overfeeding with high, low or normal protein content
Study: NCT03010774

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Risk Stratification
Description: Every night, subjects will be risk stratified into low-risk or medium- to high-risk using a physiologic risk score, eCART. Subjects who meet the low-risk criteria will not be woken up for routine nighttime vitals (typically at midnight and at 4 am). However, subjects will continue to be woken up for laboratory draws, procedures, or treatments as per usual. Subjects who are medium- to high-risk will continue to be woken up at night for routine nighttime vitals. Alarms for all subjects, including low-risk subjects, will continue to alert nurses in real-time. If the primary nurse of a low-risk subject is alerted of an alarm, the nurse will have to go into the subject's room to turn off the alarm and therefore check on the patient.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: The subject will continue to receive routine vital sign measurements and charting, standard for the ward or according to the physician orders, including routine spot-check vital signs, regardless of risk level.
Study: NCT01798316

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV Acetaminophen
Description: Single dose, 1000g mg infusion over 15 minutes plus standard of care pain management regimen

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Standard of care pain management regimen, no IV Acetaminophen,
Study: NCT02118181

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: HMB
Study: NCT01808820

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dendritic Cell Vaccine
Description: Between 1.2 to 12 million DC per dose administered once a week via intradermal injection for 4 weeks.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dendritic Cell Vaccine
Description: Between 1.2 to 12 million DC per dose administered once a week via intradermal injection for 4 weeks.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tumor Lysate
Description: Post-DC Vaccine therapy. Up to 1.5 mg of Lysate of tumor per dose administered via intradermal injection at intervals defined by study protocol.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tumor Lysate
Description: Post-DC Vaccine therapy. Up to 1.5 mg of Lysate of tumor per dose administered via intradermal injection at intervals defined by study protocol.
Study: NCT00370383

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Satraplatin
Description: satraplatin 100 mg/m2 orally once daily for 5 consecutive days (days 1-5)followed by erlotinib 150mg/day for 14 consecutive days (days 8-21).~Satraplatin JM-216, bis-aceto-ammine dischlorocyclohexylamine platinum)is a third-generation platinum analogue with activity following oral administration. The molecular formula for satraplatin is C10H22N2Cl2O4Pt, which is structured as an octahedral platinum compound.
Study: NCT01505166

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vigil™ Vaccine
Description: Patients will receive 1 x 10\^7 cells (Group A) or placebo (Group B) via intradermal injection for a minimum of 5 doses and a maximum of 12 doses starting post-surgery Week 4-8 (C1W1D1) and continuing C1W3D1, C2W3D1, then every 28 days. Starting C1W4D1, all patients will receive modified FOLFOX6 (oxaliplatin 85 mg/m2 D1, l-leucovorin 200 mg/m2 D1, fluorouracil 400 mg/m2 IV bolus (or short infusion) D1, fluorouracil 2400 mg/m2 46 hours continuous infusion every 14 days x 6 cycles (1 cycle = 4 weeks).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vigil™ Vaccine
Description: Patients will receive 1 x 10\^7 cells (Group A) or placebo (Group B) via intradermal injection for a minimum of 5 doses and a maximum of 12 doses starting post-surgery Week 4-8 (C1W1D1) and continuing C1W3D1, C2W3D1, then every 28 days. Starting C1W4D1, all patients will receive modified FOLFOX6 (oxaliplatin 85 mg/m2 D1, l-leucovorin 200 mg/m2 D1, fluorouracil 400 mg/m2 IV bolus (or short infusion) D1, fluorouracil 2400 mg/m2 46 hours continuous infusion every 14 days x 6 cycles (1 cycle = 4 weeks).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will receive 1 x 10\^7 cells (Group A) or placebo (Group B) via intradermal injection for a minimum of 5 doses and a maximum of 12 doses starting post-surgery Week 4-8 (C1W1D1) and continuing C1W3D1, C2W3D1, then every 28 days. Starting C1W4D1, all patients will receive modified FOLFOX6 (oxaliplatin 85 mg/m2 D1, l-leucovorin 200 mg/m2 D1, fluorouracil 400 mg/m2 IV bolus (or short infusion) D1, fluorouracil 2400 mg/m2 46 hours continuous infusion every 14 days x 6 cycles (1 cycle = 4 weeks).
Study: NCT01808820

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imiquimod
Description: 5% topical cream applied to vaccine site before and after administrations of DC vaccine or lysate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imiquimod
Description: 5% topical cream applied to vaccine site before and after administrations of DC vaccine or lysate
Study: NCT02964741

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator
Description: non-invasive brain stimulation (active protocol)

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Comparator
Description: non-invasive brain stimulation (sham protocol)
Study: NCT01808820

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Leukapheresis
Description: Baseline, post-surgery blood draw via catheter to obtain peripheral blood mononuclear cells (PBMCs) from which Dendritic cells will be obtained.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Leukapheresis
Description: Baseline, post-surgery blood draw via catheter to obtain peripheral blood mononuclear cells (PBMCs) from which Dendritic cells will be obtained.
Study: NCT02182635

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ba253BINEB
Study: NCT04434300

Intervention type: DRUG
Group type: OTHER
Intervention: Daptomycin
Description: Compare the pharmacokinetic of subcutaneous (SC) and intravenous (IV) routes in the same patient.

Intervention type: DRUG
Group type: OTHER
Intervention: Daptomycin
Description: Compare the pharmacokinetic of subcutaneous (SC) and intravenous (IV) routes in the same patient.
Study: NCT03420495

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Decision-Making Tasks
Description: All participants will receive a structured diagnostic assessment and complete self-report questionnaires about cognitive factors, decision-making styles, and anxiety/mood symptoms. They then will be guided through three judgment and decision-making (JDM) paradigms (the Risk and Ambiguity Task, the Beads Task, and the Balloon Analogue Risk Task), each of which each has been modified to differ by whether the likelihood of potential adverse outcomes is provided (or whether it remains ambiguous).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Decision-Making Tasks
Description: All participants will receive a structured diagnostic assessment and complete self-report questionnaires about cognitive factors, decision-making styles, and anxiety/mood symptoms. They then will be guided through three judgment and decision-making (JDM) paradigms (the Risk and Ambiguity Task, the Beads Task, and the Balloon Analogue Risk Task), each of which each has been modified to differ by whether the likelihood of potential adverse outcomes is provided (or whether it remains ambiguous).
Study: NCT03239951

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iTind
Description: temporary implant
Study: NCT00801723

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide MMX 6 mg Tablet
Description: Budesonide MMX 6 mg Tablet once daily.
Study: NCT01809275

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QBECO

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT05031234

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anaesthesia without opiates
Description: Anaesthesia without opiates for patients undergoing laparoscopic colectomy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: anaesthesia with morphine
Description: anaesthesia with morphine for patients undergoing laparoscopic colectomy
Study: NCT04122885

Intervention type: COMBINATION_PRODUCT
Intervention: PIPAC with oxaliplatin
Description: Oxaliplatin 92 mg/m2 BSA, applied as an aerosol for 30 min under normothermic conditions at 12-15 mmHg pressure

Intervention type: PROCEDURE
Intervention: Cytoreductive surgery and Hyperthermic IntraPeritoneal Chemotherapy
Description: If complete cytoreduction possible (CC-0). Application time 60 min, T 41-43 °C
Study: NCT02362139

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: The study group
Description: 200 pregnant women, 18-45 years old, 37-41 weeks of gestation, in spontaneous labor, which were treated with 80 mg of Intra-muscular (IM) Papverine during the latent phase of labor (cervical dilatation\<4cm).
Study: NCT04172207

Intervention type: OTHER
Intervention: Sampling
Description: After periodontal parameters measured, smear samples were obtained from the buccal mucosa and keratinized gingiva, and then a gingival biopsy was performed from the upper premolars.
Study: NCT00586313

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tru-cut biopsy
Description: Tru-cut biopsy may be an alternative to percutaneous and transjugular liver biopsy.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tru-cut
Description: Tru-cut may be an alternative to percutaneous and transjugular liver biopsy.
Study: NCT02079649

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL-53817 Ophthalmic Solution, 0.1%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL-78843 Ophthalmic Solution, 0.03%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone Ophthalmic Suspension, 0.1%

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AL-53817 Vehicle
Description: Inactive ingredients used for masking purposes
Study: NCT01291628

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: socks containing copper-oxide fibers
Description: The patients will use a sock which contains copper fibers. The socks are sold in the free market (different Pharma stores) for various purposes such as prevention of diabetic foot. It is a product of Cupron company EPA :84542-2, 84542-3 from April 30 2009.
Study: NCT02109575

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood Draw of up to 10 ml
Description: In a laboratory setting, the blood will be spun for plasma and buffy coat, DNA will be extracted for processing using the diagnostic test. The results of the test are not provided back to the clinical setting.
Study: NCT04160741

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Radiation and warm environment
Description: Exposure to hot environment (30°C WBGT) with radiation (800 W/m2)~Exposure for 03:20:00:~* rest (two hours)~* work (cycling) at 100 W (one hour)~* recovery (twenty minutes)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Warm environment
Description: Exposure to hot environment (30°C WBGT) with radiation (0 W/m2)~Exposure for 03:20:00:~* rest (two hours)~* work (cycling) at 100 W (one hour)~* recovery (twenty minutes)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Neutral environment with radiation
Description: Exposure to neutral environment (20°C WBGT) with radiation (800 W/m2)~Exposure for 03:20:00:~* rest (two hours)~* work (cycling) at 100 W (one hour)~* recovery (twenty minutes)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neutral environment without radiation
Description: Exposure to neutral environment (20°C WBGT) with radiation (0 W/m2)~Exposure for 03:20:00:~* rest (two hours)~* work (cycling) at 100 W (one hour)~* recovery (twenty minutes)
Study: NCT03048994

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Glutamine
Description: * Patients randomised to receive glutamine supplementation will receive IV glutamine (0.5g/kg body weight/day) continuously over 24 hours.~* IV glutamine will be administered for 5 days or less if death ensues prior to 5 days or transferred to another hospital prior to 5 days. IV glutamine will be continued even if the patient is transferred outside the ICU but within the hospital.~* An intravenous saline solution that is identical in volume, color and consistency will be administered to the placebo group with the same dosing regimen and duration.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: * Nutritional support will be continued as per managing ICU team discretion.~* Management of severe sepsis will be continued as per managing ICU team discretion.~* Weaning patients from mechanical ventilation will be done as per managing ICU team discretion.~* To minimise differences between centers, active dissemination of practice guidelines for nutritional support, sepsis management and weaning will be carried out.
Study: NCT02809599

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DIZZTINCT
Description: The intervention, DIZZTINCT, is a multi-faceted educational and care-process based intervention designed to improve the guideline-concordant care of patients with BPPV in the emergency department. The intervention includes six main components: the recruitment and training of local champions who will serve as colleague experts in the community; interactive hands-on educational sessions that address BPPV mechanisms, evidence and practice; a high-yield decision-aid web application for self study and point of care use; development of a referral network for follow up care; follow-up educational sessions to review successes and barriers amongst the intervention group; and other resources developed locally in partnership with the community medical providers.
Study: NCT03617471

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Venopuncture for PK profiling
Description: Blood samples at T0, T0.5, T1, T2, T4, T6

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Venopuncture for PK profiling
Description: Blood samples at T0, T0.5, T1, T2, T4, T6
Study: NCT03450824

Intervention type: OTHER
Intervention: No intervention
Description: The standardized standing whole-lower-extremity radiographs, the knee lateral view and skyline view of the participants will be taken.

Intervention type: OTHER
Intervention: No intervention
Description: The standardized standing whole-lower-extremity radiographs, the knee lateral view and skyline view of the participants will be taken.
Study: NCT02608892

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BSweet2Babies video
Description: Mothers (and partners if possible) will view the brief BSweet2Babies video on electronic notebooks in French or English, as per parent/s' preference.
Study: NCT03932591

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: kinesio taping method
Description: Kinesio tape is an elastic, adhesive, hypo-allergenic, latex-free tape. Kinesio taping method is rehabilitative taping technique. One of the purposes of this technique is to facilitate or inhibit the muscles.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham kinesio taping
Description: Sham kinesio tape will be used for controlled group. 2,5 cm width, 5 cm length, skin color 2 pieces kinesio tape will be applied on medial and lateral head of gastrocnemius muscle without stretch. 5 cm length, 5 cm width, skin color 1 piece kinesio tape will be a
Study: NCT02368730

Intervention type: DRUG
Intervention: desmopressin
Study: NCT02085486

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound-assisted puncture
Description: Portable ultrasound device
Study: NCT01865942

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: open surgery
Description: The to surgical procedures are individually well know, but the outcome of the procedures in respect to perioperative bleeding and change in quality of life has to our knowledge not been compared.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Minimal access surgery
Description: The to surgical procedures are individually well know, but the outcome of the procedures in respect to perioperative bleeding and change in quality of life has to our knowledge not been compared.